MedTrace Logo

Comparison Between Mobithron® and Crystalline Glucosamine Sulphate in Patients With Knee Osteoarthritis

NCT07717957 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-07-22

No results posted yet for this study

Summary

Knee osteoarthritis is a common degenerative joint disorder that causes pain, functional limitation, and reduced quality of life. This prospective, randomized, open-label, parallel-group study was conducted to compare the clinical effectiveness and safety of Mobithron®, a multi-component oral formulation containing hyaluronic acid matrix, undenatured type II collagen, and Boswellia serrata extract, with crystalline glucosamine sulphate in patients with primary knee osteoarthritis. Participants received either Mobithron® or crystalline glucosamine sulphate for three months in addition to a standardized rehabilitation programme. Clinical outcomes were assessed at baseline, Week 2, Week 4, and Month 3. The primary outcome was change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score. Secondary outcomes included pain severity measured using the Visual Analogue Scale (VAS) and safety assessment through adverse event monitoring.

Conditions

Interventions

DIETARY_SUPPLEMENT

Mobithron®

Mobithron® is an oral nutraceutical formulation containing hyaluronic acid matrix (Mobilee® 80 mg, providing 45 mg hyaluronic acid), undenatured type II collagen (10 mg), and Boswellia serrata extract (ApresFlex™ 100 mg). Participants received one oral dose daily for 3 months in addition to a standardized rehabilitation programme.

DIETARY_SUPPLEMENT

Crystalline Glucosamine Sulphate

Crystalline glucosamine sulphate 1500 mg was administered orally once daily for 3 months in addition to the same standardized rehabilitation programme.

Sponsors & Collaborators

  • International Islamic University Malaysia

    collaborator OTHER

  • BREGO Life Sciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2025-09-30
Completion
2025-09-30

Countries

  • Malaysia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07717957 on ClinicalTrials.gov